• Logo
  • SBMUJournals

The association of serum level of CTRP1 with Common Bile Duct Diameter and Other Manifestations in Patients with Non-alcoholic Fatty Liver

Reyhane Ebrahimi, Shahabedin Zand, Mehrnoosh Shanaki
16

Views

PDF

Abstract

Background: Nonalcoholic fatty liver diseases (NAFLD) is one of the main chronic liver diseases and raises the risk of morbidity and mortality due to its inevitable outcomes. Understanding the clinical manifestations of the liver is critical to identify NAFLD patients with the greatest risk of developing nonalcoholic steatohepatitis and cirrhosis. In the liver, C1q/TNF-related protein 1 (CTRP1) modulates both glucose and lipid metabolism and improves insulin sensitivity which may affect the pathologies of the liver.

 Materials and Methods: This study was conducted on 22 patients with NAFLD confirmed by ultrasonography and 21 healthy subjects. Clinical and histological variables were analyzed. The ultrasonography procedure was used to quantity Common bile duct (CBD). Liver stiffness (LS) was measured by transient elastography.

Results: There was a significant difference in CTRP1 levels between NAFLD patients and controls (p=0.032). Moreover, there was a significant positive correlation between CTRP1 level and liver enzymes including AST (r=0.667; p=0.001), ALT (r=0.433; p=0.044), and γ-GT (r=0.428; p=0.047) in NAFLD patients. There was also a significant positive correlation between CTRP1 level and CBD (r= 0.469; p=0.028) in NAFLD patients. Moreover, the largest CBD was measured as 5.99 mm.

Conclusion: It seems that CTRP1 is a novel adipokine related to the pathogenesis of NAFLD and is associated with the clinical manifestations of the liver such as liver enzymes, and CBD.


Keywords

Nonalcoholic fatty liver diseases (NAFLD), C1q/TNF-related protein 1 (CTRP1), Common bile duct (CBD), Liver stiffness (LS).

References

Benedict, M. and X. Zhang, Non-alcoholic fatty liver disease: An expanded review. World J Hepatol, 2017. 9(16): p. 715-732.

Adolph, T.E., et al., Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions. International journal of molecular sciences, 2017. 18(8): p. 1649.

Buechler, C., et al., Adipokines in Liver Cirrhosis. International journal of molecular sciences, 2017. 18(7): p. 1392.

Emamgholipour, S., et al., The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetol Metab Syndr, 2015. 7: p. 108.

Shabani, P., et al., Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance? PLoS One, 2015. 10(3): p. e0118650.

Antuna-Puente, B., et al., Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab, 2008. 34(1): p. 2-11.

Meshkani, R. and K. Adeli, Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem, 2009. 42(13-14): p. 1331-46.

Han, S., et al., Circulating CTRP1 Levels in Type 2 Diabetes and Their Association with FGF21. Int J Endocrinol, 2016. 2016: p. 5479627.

Skoczylas, K. and A. Pawełas, Ultrasound imaging of the liver and bile ducts - expectations of a clinician. J Ultrason, 2015. 15(62): p. 292-306.

Rajapaksha, I.G., P.W. Angus, and C.B. Herath, Current therapies and novel approaches for biliary diseases. World J Gastrointest Pathophysiol, 2019. 10(1): p. 1-10.

Purohit, T. and M.S. Cappell, Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol, 2015. 7(7): p. 926-41.

Purohit, T. and M.S. Cappell, Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol, 2015. 7(7): p. 926-41.

Rajapaksha, I.G., P.W. Angus, and C.B. Herath, Current therapies and novel approaches for biliary diseases. World J Gastrointest Pathophysiol, 2019. 10(1): p. 1-10.

Lal, N., S. Mehra, and V. Lal, Ultrasonographic measurement of normal common bile duct diameter and its correlation with age, sex and anthropometry. J Clin Diagn Res, 2014. 8(12): p. Ac01-4.

Mahour, G.H., K.G. Wakim, and D.O. Ferris, The common bile duct in man: its diameter and circumference. Ann Surg, 1967. 165(3): p. 415-9.

Cooperberg, P.L., High-resolution real-time ultrasound in the evaluation of the normal and obstructed biliary tract. Radiology, 1978. 129(2): p. 477-80.

Parulekar, S.G., Ultrasound evaluation of common bile duct size. Radiology, 1979. 133(3 Pt 1): p. 703-7.

Graham, M.F., et al., The size of the normal common hepatic duct following cholecystectomy: an ultrasonographic study. Radiology, 1980. 135(1): p. 137-9.

Angulo, P., et al., Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol, 2004. 41(6): p. 943-9.

Cohen, J.C., J.D. Horton, and H.H. Hobbs, Human fatty liver disease: old questions and new insights. Science, 2011. 332(6037): p. 1519-23.

Fujii, H. and N. Kawada, Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol, 2012. 47(3): p. 215-25.

Hossain, N., et al., Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol, 2009. 7(11): p. 1224-9, 1229.e1-2.

Podrini, C., et al., Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). Curr Pharm Des, 2013. 19(15): p. 2737-46.

Carter-Kent, C., N.N. Zein, and A.E. Feldstein, Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol, 2008. 103(4): p. 1036-42.

Jarrar, M.H., et al., Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2008. 27(5): p. 412-21.

Krawczyk, K., et al., Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J Physiol Pharmacol, 2009. 60 Suppl 3: p. 71-5.

Seldin, M.M., S.Y. Tan, and G.W. Wong, Metabolic function of the CTRP family of hormones. Rev Endocr Metab Disord, 2014. 15(2): p. 111-23.

Chalupova, L., A. Zakovska, and K. Adamcova, Development of a novel enzyme-linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a pilot study: measurement of serum CTRP1 in healthy donors and patients with metabolic syndrome. Clin Biochem, 2013. 46(1-2): p. 73-8.

Lasser, G., et al., C1qTNF-related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen. Blood, 2006. 107(2): p. 423-30.

Schaffler, A. and C. Buechler, CTRP family: linking immunity to metabolism. Trends Endocrinol Metab, 2012. 23(4): p. 194-204.

Wong, G.W., et al., Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J, 2008. 416(2): p. 161-77.

Chalupova, L., A. Zakovska, and K. Adamcova, Development of a novel enzyme-linked immunosorbent assay (ELISA) for measurement of serum CTRP1: a pilot study: measurement of serum CTRP1 in healthy donors and patients with metabolic syndrome. Clin Biochem, 2013. 46(1-2): p. 73-8.

Pan, X., et al., Circulating complement-C1q TNF-related protein 1 levels are increased in patients with type 2 diabetes and are associated with insulin sensitivity in Chinese subjects. PLoS One, 2014. 9(5): p. e94478.

Yuasa, D., et al., Association of circulating C1q/TNF-related protein 1 levels with coronary artery disease in men. PLoS One, 2014. 9(6): p. e99846.

Peterson, J.M., et al., CTRP1 protein enhances fatty acid oxidation via AMP-activated protein kinase (AMPK) activation and acetyl-CoA carboxylase (ACC) inhibition. J Biol Chem, 2012. 287(2): p. 1576-87.

Kim, K.Y., et al., Tumor necrosis factor-alpha and interleukin-1beta increases CTRP1 expression in adipose tissue. FEBS Lett, 2006. 580(16): p. 3953-60.

Ma, K., et al., Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem, 2002. 277(38): p. 34658-61.

Maeda, N., et al., Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med, 2002. 8(7): p. 731-7.

Wong, G.W., et al., Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J, 2008. 416(2): p. 161-77.

Pagano, C., et al., Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol, 2005. 152(1): p. 113-8.

Wree, A., et al., Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury




DOI: https://doi.org/10.22037/amls.v4i1.26273

Refbacks

  • There are currently no refbacks.